Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Cancer of Head and Neck; Cancer of the Head; Cancer of the Neck

Study type: Observational

Funder types: Industry

Identifiers

NCT03569436

CA209-8DD

Details and patient eligibility

About

Non-interventional study in Japan of participants with HNC recurring or that has spread and who are treated with nivolumab

Enrollment: 262 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recurrent/metastatic HNC patients with disease progression on or after a platinum-based therapy treated with nivolumab at least once from 01-Jul-2017 through 31-Dec-2017

Exclusion criteria

• History of participation in any clinical trials prior- or post-nivolumab treatment

Other protocol defined inclusion/exclusion criteria could apply

Trial design

262 participants in 1 patient group

Metastatic head and neck participants in Japan

Description:

Study in Japan targeting recurrent/metastatic HNC patients who are treated with nivolumab